Form 4: Kairos Pharma CSO Neil Bhowmick Receives RSU Grant

Kairos Pharma's Chief Scientific Officer, Neil Bhowmick, was granted 171,756 restricted stock units under the company's 2023 Equity Incentive Plan.

Summary

• Neil Bhowmick, Chief Scientific Officer of Kairos Pharma, LTD. (KAPA), acquired 171,756 restricted stock units (RSUs).
• The transaction date for this acquisition was October 8, 2025.
• The RSUs were issued under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan at a price of $0.00 per unit.
• These 171,756 RSUs are scheduled to vest on the first anniversary of the grant date, which is October 8, 2026.
• Following this transaction, Neil Bhowmick beneficially owns a total of 1,311,739 securities.
• This total beneficial ownership consists of 1,135,317 shares of common stock and 176,422 RSUs that remain subject to vesting.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it represents a routine executive compensation event that aligns management's interests with shareholders through equity incentives, without indicating any negative operational or financial news.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the Chief Scientific Officer's long-term incentives with shareholder value, as the value of the RSUs is tied to the company's stock performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged plan for the purchase or sale of equity securities, which can reduce concerns about opportunistic insider trading.

Future Outlook

The vesting schedule for the granted RSUs indicates a future milestone on October 8, 2026, when these units will convert into common stock, subject to continued employment and plan terms.

Industry Context

The grant of Restricted Stock Units (RSUs) is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key scientific and executive talent. This form of equity compensation aligns the interests of the Chief Scientific Officer with the long-term success and innovation goals of Kairos Pharma, a typical strategy for companies in this sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Scientific Officer's financial interests with the company's long-term stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: This grant is part of an equity incentive plan, which can signal a commitment to retaining key talent and may influence broader employee compensation strategies.

Next Steps

• The 171,756 Restricted Stock Units are scheduled to vest on October 8, 2026, converting into common stock upon fulfillment of vesting conditions.

Key Dates

Keywords

Kairos Pharma, KAPA, Restricted Stock Units, RSU Grant, Insider Transaction, Executive Compensation, Equity Incentive Plan, Neil Bhowmick, Chief Scientific Officer